Anti-HPV 11 L1 monoclonal antibody (set) (CABT-B8804)

Mouse Anti-HPV 11 L1 monoclonal antibody (set) for ELISA, Neut, Screening

Specifications


Host Species
Mouse
Antibody Isotype
34C9-IgG1; 35C1-IgG1; 35H5-IgG1; 34E5-IgG1; 40C5-IgG1; 34D10-IgG1
Clone
34C9; 35C1; 35H5; 34E5; 40C5; 34D10
Species Reactivity
HPV 11
Immunogen
E. coli expressed HPV6 L1 VLP
Conjugate
Unconjugated

Applications


Application Notes
IC50(μg/ml) for Neut: 34C9-4.27; 35C1-15.87; 35H5-743; 34E5-43
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.

Data Examples


IC50 (μg/ml) of 34C9 for Neut is 4.27
IC50 (μg/ml) of 35C1 for Neut is 15.87
IC50 (μg/ml) of 35H5 for Neut is 743
IC50 (μg/ml) of 34E5 for Neut is 43

Target


Alternative Names
HPV; L1; major capsid L1 protein; HPV-11; HPV-11 capsid; HPV11 capsid protein

Citations


Have you cited CABT-B8804 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling


We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Human papillomavirus (HPV) vaccine utilization among adults (18-29 years), BRFSS 2015

VACCINE

Authors: Wiener, R. Constance; Findley, Patricia A.; Shen, Chan; Dwibedi, Nilanjana; Sambamoorthi, Usha

Human papillomavirus (HPV) vaccination acceptance is hampered by fears and conflicting attitudes about the need for and safety of vaccine. There are also ethical dilemmas associated with vaccinating adolescents for a sexually transmitted disease despite future cancer risk. The purpose of this research was to determine HPV vaccination acceptance/hesitancy among young adults. Behavioral Risk Factor Surveillance System 2015 data were used. During 2015, 83.1% of adults ages 25-29 years did not receive any HPV vaccination; the UOR was 3.47; 95% CI = 2.11, 5.70) compared to adults 18-24 years. There is a need to accelerate public health messaging/campaigns to increase HPV vaccination rates. (C) 2020 Elsevier Ltd. All rights reserved.

Binge drinking, HIV/HPV co-infection risk, and HIV testing: Factors associated with HPV vaccination among young adults in the United States

PREVENTIVE MEDICINE

Authors: Olusanya, O. O.; Wigfall, L. T.; Rossheim, M. E.; Tomar, A.; Barry, A. E.

Human papillomavirus (HPV) is a common sexually transmitted infection. Binge drinkers often engage in HIV/ HPV co-infection high-risk behaviors. We examined the association between binge drinking, HIV/HPV co-infection risk, HIV testing and HPV vaccination among young adults. Data from the 2017 Behavioral Risk Factor Surveillance System survey were examined. Participants (N = 430/450,016; 0.11%) were HPV vaccine-eligible young adults ages 18-26 years. Multivariable logistic regression examined the association between binge drinking in the past 30 days, HIV/HPV co-infection high-risk risk behaviors, HIV testing, and HPV vaccination (initiated/completed, unvaccinated) among young adults. Respondents were primarily cisgender (99.8%), non-Hispanic White (41.4%), employed (46.2%) or student (35.4%), and insured (68.2%). Most did not binge drink (55.2%). The majority did not engage in HIV/HPV co-infection high-risk risk behaviors (78.2%). More than one-half had never been tested for HIV (59%) nor vaccinated against HPV (60.6%). Although binge drinkers (44.8%) were significantly more likely to engage in HIV/HPV co-infection high-risk behaviors (OR = 2.1; 95% CI: 1.0-4.5), binge drinking was not positively associated with HIV testing (OR = 0.98; 95% CI: 0.63-1.53). After adjusting for demographics and HIV/HPV co-infection high-risk behaviors, one (aOR = 2.71; 95% CI: 1.11-6.65) and two episodes (aOR = 3.05; 95% CI: 1.26-7.41) of binge drinking in the past 30 days were significantly associated with HPV vaccination uptake. Positive associations between HPV vaccination and participants having an HIV test in 2017 (aOR = 3.86; 95% CI: 1.42-10.55) and before 2017 (aOR = 2.62; 95% CI: 1.23-5.56) were also statistically significant. Because young adult binge drinkers are more likely to engage in HIV/HPV co-infection high-risk behaviors, promoting HPV vaccination and HIV testing are important public health objectives.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket